Forte Biosciences (FBRX) Return on Capital Employed (2017 - 2026)
Forte Biosciences (FBRX) reported Return on Capital Employed of 40.24% for Q1 2026, down 557.0% year-over-year from 8.81% in Q1 2025, and down 94.0% quarter-over-quarter from 20.74% in Q4 2025.
Forte Biosciences (FBRX) Return on Capital Employed (2017 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 10 years of Return on Capital Employed data on file, last reported at 40.24% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 40.24%, down 557.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 40.24% (down 557.0% YoY), and the FY2025 annual result was 27.91%, down 982.0% from the prior year.
- Return on Capital Employed fell to 40.24% in Q1 2026 per FBRX's latest filing, from 20.74% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 20.74% in Q4 2025 and troughed at 265.28% in Q3 2024.
- A 5-year average of 70.36% and a median of 42.39% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 16845 bps in 2024, then jumped 23813 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 34.41% in 2022, then plunged by 137 bps to 81.7% in 2023, then jumped by 70 bps to 24.29% in 2024, then increased by 15 bps to 20.74% in 2025, then tumbled by 94 bps to 40.24% in 2026.
- Business Quant data shows FBRX's Return on Capital Employed at 40.24% in Q1 2026, 20.74% in Q4 2025, and 27.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | -40.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.24% |
| Dec 31, 2025 | -20.74% |
| Sep 30, 2025 | -27.15% |
| Jun 30, 2025 | -21.23% |
| Mar 31, 2025 | -34.68% |
| Dec 31, 2024 | -24.29% |
| Sep 30, 2024 | -265.28% |
| Jun 30, 2024 | -186.74% |
| Mar 31, 2024 | -103.94% |
| Dec 31, 2023 | -81.70% |
| Sep 30, 2023 | -96.83% |
| Jun 30, 2023 | -87.72% |
| Mar 31, 2023 | -51.24% |
| Dec 31, 2022 | -34.41% |
| Sep 30, 2022 | -30.54% |
| Jun 30, 2022 | -42.39% |
| Mar 31, 2022 | -46.92% |
| Dec 31, 2021 | -49.29% |
| Sep 30, 2021 | -48.88% |
| Jun 30, 2021 | -38.44% |